HIV Therapy

Triangle Plans NDA Submission for Coviracil, Discontinues Work On Coactinon

Published in AIDS Weekly, February 11th, 2002

Triangle Pharmaceuticals, Inc., (VIRS) has provided updated information on the development of two of its HIV compounds, Coviracil and Coactinon.

Following recent discussions with the U.S. Food and Drug Administration (FDA), Triangle now plans to submit a New Drug Application (NDA) in fall 2002 for Coviracil in the treatment of HIV. The company expects Coviracil to become its first product for which an NDA is submitted, marking a critical milestone in the company's history.

Triangle further intends to terminate development of Coactinon, another of its HIV compounds. The company recently completed a planned interim analysis of 24-week data from study...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2002-02-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry